Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the pricing of underwritten offerings of (i) 9,561,905 shares of its common stock at a price of $0.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that the first patient has been treated in an investigator-sponsored pilot study of vosaroxin and cytarabine in adult patients …
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that the European Patent Office (EPO) has granted European Patent No.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that two posters detailing preclinical data from its BTK and PDK1 inhibitor programs were presented on Sunday, November 8th …
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) reported financial results for the third quarter ended September 30, 2015.
In a research report issued today, Cantor analyst Mara Goldstein reiterated a Hold rating on shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) with a $2.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) price target has been increased at Roth Caputal by research analyst Joseph Pantginis from $4.
In a research report published Friday, Wedbush analyst David Nierengarten maintained a Neutral rating on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) with a $2.
